The Th17 and T reg cells were evaluated by flow cytometry and reported as a percentage of total CD4 + cells. In TILs from early breast cancer patients (n = 12), the frequency of Th17 cells was significantly higher than in PBMCs (14.5 ± 7.2% versus 6.9 ± 2.1%). In TILs from patients with advanced breast cancer (n = 15), the frequency of Th17 cells was also significantly higher than that in PBMCs (9.1 ± 5.7% versus 3.2 ± 2.3%) but lower compared with early disease. The Th17/T reg ratio in TILs was markedly increased in early versus advanced disease. In conclusion, Th17 and T reg cell accumulation in the tumour microenvironment of breast cancer occurred in early disease; Th17 cell infiltration gradually decreased and T reg cells accumulated with disease progression.
Introduction
In many countries, breast cancer is the most common malignancy in women. 1 Despite efforts to introduce new treatment modalities, such as surgery combined with chemotherapy or chemoradiotherapy, the control of advanced breast cancer remains difficult. 2 The grade of CD3 + tumourinfiltrating lymphocytes (TILs) has been shown to correlate with a favourable outcome in patients with several types of cancer, including breast cancer. 3, 4 Thus, it is important to understand immunoregulation in breast cancer in order to develop novel treatment strategies or to improve the efficacy of standard therapy.
Naïve CD4 + T helper (Th) cells can develop into four types of T-cells: Th1, Th2, Th17 or regulatory T-cells (T reg ), based on the local cytokine milieu. The balance between these four types of cell is important for the regulation of immune responses in several mouse models, 5 -7 although information in humans remains limited and controversial. Th17 cells are characterized as interleukin (IL)-17-producing CD4 + T-cells that also produce IL-21, IL-22 and IL-26. 7 -9 Indeed, IL-21, and also IL-23, were reported to be related J Wang, D Cai, B Ma et al.
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to IL-17 regulation. 7 In addition, retinoid orphan nuclear receptor has been described as a key regulator of Th17 cell lineage differentiation, and Th17 cells are believed to play critical roles in the development of autoimmunity and allergic reactions. 10 Information on Th17 cells in cancer-bearing hosts remains limited although some studies suggest that they may play active roles in antitumour immunity. 11 -16 Regulatory T-cells play important roles in immunological self-tolerance and are functionally immunosuppressive subsets of T-cells. 17, 18 There is accumulating evidence that an increased population of T reg cells in TILs or peripheral blood mononuclear cells (PBMCs) is one reason for impaired antitumour immunity in cancer-bearing hosts. 19 -24 The balance between T reg and Th17 cells is a key factor that regulates Th cell function relating to the Th1/Th2 shift in autoimmune disease and graft versus host disease. 25 There is, however, limited information on the balance between T reg and Th17 cells in cancer patients. 26, 27 Thus, the present study was designed to investigate the distribution of Th17 cells in relation to T reg cells in TILs and PBMCs taken from patients with breast cancer.
Patients and methods

PATIENTS
Consecutive patients with breast cancer who underwent surgery at Huashan Hospital, Fudan University, Shanghai, China, between June 2009 and February 2010 were enrolled in the study. The study group comprised chemotherapy-and radiotherapy-naïve patients with breast cancer, classified as stage I (early stage disease) and stages II -IV (advanced stage disease) according to the sixth edition of the American Joint Committee on Cancer Staging Manual. 28 The control group consisted of age-and non-related sex-matched healthy women with no signs or symptoms of breast cancer who were recruited among patients' escorts and hospital staff. Patients with autoimmune diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus), chronic infections (e.g. human immunodeficiency virus infection, tuberculosis), bone marrow involvement, and those who were anticoagulant and antithrombotic drug users or who had received immunosuppressive treatment were excluded. Review of pathology reports confirmed the breast cancer diagnoses.
All patients gave written informed consent and the study was approved by the Ethics Committee of Huashan Hospital, Fudan University.
CELL PREPARATION
Lymphocytes were harvested from tumours by a discontinuous density gradient method. Briefly, tumours were removed aseptically and minced with scissors into 1 -2 mm 3 pieces. The minced tumours were then stirred in 40 ml complete RPMI-1640 medium containing 40 mg collagenase type IV, 4 mg deoxyribonuclease and 100 U hyaluronidase (all from Sigma-Aldrich, St Louis, MO, USA) for 3 h at room temperature. The tumour cell suspension was filtered through a nylonmesh screen with 50-µm pores to remove cell clumps and the filtrate was then centrifuged at 250 g for 10 min. The cell pellet was washed twice with serum-free RPMI-1640 and resuspended in complete RPMI-1640. A 4-ml aliquot of disaggregated tumour cell suspension was placed on top of the gradient formed by overlapping a cushion of 100% Ficoll-Paque™ (Pharmacia Fine Chemicals, Piscataway, NJ, USA) with an equal volume of 75% Ficoll-Paque™ in RPMI-1640. Gradients (14 ml) were centrifuged at 800 g for 30 min at room temperature. The distinct T reg and Th17 cells in breast cancer band formed at the interface between 75% and 100% Ficoll-Paque™ contained the lymphocytes and was collected and washed three times in fresh medium (RPMI 1640 containing 10% fetal calf serum). The lymphocytes were used immediately.
At the time of tumour collection, peripheral blood was drawn into heparincontaining Vacutainer™ tubes (Becton Dickinson, Franklin Lakes, NJ, USA), diluted 2 : 1 with 1 × Dulbecco's 0.01 M phosphatebuffered saline, pH 7.3, without calcium or magnesium (Mediatech, Manassas, VA, USA). It was then separated by centrifugation over a Ficoll-Paque™ density gradient for 20 min at 1000 g at room temperature. The PBMCs were collected, washed and resuspended in RPMI-1640 containing 10% fetal calf serum ready for use.
FLOW CYTOMETRIC ANALYSIS OF TH17 CELLS
To analyse the prevalence of Th17 cells, lymphocytes were incubated in RPMI-1640 medium in the presence of phorbol 12myristate 13-acetate (50 µg/ml; Sigma-Aldrich), ionomycin (800 µg/ml; Sigma-Aldrich) and monensin (2 mM; eBioscience, San Diego, CA, USA) for 4 h at 37°C. Cells were then stained with allophycocyaninconjugated anti-CD4 antibodies (R&D Systems, Minneapolis, MN, USA) for 30 min at 4°C, followed by treatment with Fixation/Permeabilization Buffer (eBioscience) for 45 min at 4°C and incubation with a IL-17A-phycoerythrin (PE) monoclonal antibody (eBioscience), or mouse immunoglobulin (Ig)G1b monoclonal antibody (eBioscience) as an isotype control, for 30 min at 4°C. The number of Th17 cells was then evaluated by flow cytometry (FACSCalibur™; BD Biosciences, San Jose, CA, USA) and the frequency of Th17 cells was expressed as a percentage of the total number of CD4 + cells.
FLOW CYTOMETRIC ANALYSIS OF T REG CELLS
Naturally occurring T reg cells were characterized by CD4 and CD25 staining and the presence/absence of CD127 staining. Briefly, the single-cell suspension of lymphocytes from the band formed at the interface between 75% and 100% Ficoll-Paque™ was stained for 30 min at 4°C using a cocktail of anti-CD4-fluorescein isothiocyanate (FITC) conjugated monoclonal antibody, PE-conjugated anti-CD25 monoclonal antibody and ALEXA647labelled anti-CD127 monoclonal antibody, or ALEXA647-conjugated mouse IgG2a as an isotype control (all antibodies from eBioscience). The frequency of T reg cells was analysed using flow cytometry and expressed as a percentage of the total number CD4 + T-cells.
CYTOKINE PRODUCTION BY T CELLS
To induce cytokine production, PBMCs (5.0 × 10 5 cells) or TILs (5.0 × 10 5 cells) were incubated in 1 ml RPMI-1640 medium for 72 h at 37°C in a 48-well plate (Coaster, Cambridge, MA, USA) precoated with anti-CD3 monoclonal antibody (2.5 µg/ml, OKT3; Miltenyi Biotec, Auburn, CA, USA) and anti-CD28 monoclonal antibody (1.25 µg/ml; 15E8, Miltenyi Biotec). The supernatants were collected and stored at -70°C prior to enzyme-linked immuno sorbent assay to measure cytokine levels (human IL-17A, human IL-21 and human IL-23 [p19/p40] kits; eBioscience), carried out according to the manufacturer's recommendations.
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical package, version 15.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The unpaired Student's t-test was used to examine between-group differences.
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Correlations between values were evaluated using non-parametric Spearman's rank correlation coefficient. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS
In total, 32 consecutive patients with breast cancer were enrolled in the study. Five patients were lost to follow-up, so the final study group comprised 27 chemotherapy-and radiotherapy-naïve patients (stage I [early disease], n = 12; stages II -IV [advanced disease], n = 15). Their clinicopathological characteristics are summarized in Table 1 . The control group consisted of 14 age-and sexmatched healthy volunteers.
DISTRIBUTION OF TH17 CELLS
Representative flow cytometric data for the percentage of Th17 cells in PMBCs and TILs from the breast cancer patients are shown in Fig. 1A and 1B, respectively. In TILs from patients with early stage disease, the frequency of Th17 cells was significantly higher than in PBMCs from early breast cancer patients (mean ± SD 14.5 ± 7.2% versus 6.9 ± 2.1%; P < 0.01; Fig. 1C, 1D ). In patients with advanced disease, the frequency of Th17 cells in TILs was also significantly higher than in PBMCs (mean ± SD 9.1 ± 5.7% versus 3.2 ± 2.3%; P < 0.01; Fig. 1C, 1D ). These results indicate that Th17 cells were not only present, but also dominantly enriched in TILs from breast Fig. 1D ). In PBMCs from patients with advanced breast cancer, the frequency of Th17 cells was significantly lower than in healthy controls (mean ± SD 3.2 ± 2.3% versus 7.3 ± 2.6%; P < 0.01; Fig. 1C ). There was no significant difference in the frequency of Th17 cells in PMBCs between patients with early disease and healthy controls (mean ± SD 6.9 ± 2.1% versus 7.3 ± 2.6%; Fig. 1C ).
TABLE 1: Clinicopathological characteristics of the breast cancer patients investigated for distribution of interleukin-17-producing CD4 + T-cells (Th17 cells) and CD4 + CD25 + CD127regulatory T-cells (T reg cells) in tumour-infiltrating lymphocytes and peripheral blood mononuclear cells according to disease stage
DISTRIBUTION OF T REG CELLS
The prevalence of CD4 + CD25 + CD127 -T reg cells was evaluated by flow cytometry and expressed as a percentage of the total CD4 + cells, consistent with a previous report. 21 Representative flow cytometric data for the In TILs from patients with advanced disease, the frequency of T reg cells was significantly higher than in PBMCs from early breast cancer patients (mean ± SD 16.2 ± 4.1% versus 4.9 ± 2.6%; P < 0.01; Fig.  2C, 2D ). Furthermore, the frequency of T reg cells in TILs from patients with early breast cancer was also significantly increased compared with the frequency of T reg cells in PBMCs from advanced breast cancer patients (mean ± SD 12.0 ± 3.7% versus 4.3 ± 1.3%; P < 0.01; Fig. 2C, 2D ). In PBMCs from patients with advanced disease, the frequency of T reg cells was significantly increased compared with healthy controls (mean ± SD 4.9 ± 2.6% versus 2.1 ± 1.4%; P < 0.01; Fig. 2C ). In addition, there was a significant difference in the frequency of T reg cells in PBMCs between patients with early breast cancer and healthy controls (mean ± SD 4.3 ± 1.3% versus 2.1 ± 1.4%; P < 0.01; Fig. 2C ). 
TH17⁄T REG RATIO ACCORDING TO DISEASE PROGRESSION
Evaluation of the ratio of Th17/T reg cells showed it to be elevated in TILs in early compared with advanced breast cancer (P < 0.05; Fig. 3A ). When each individual value of the prevalence of Th17 and T reg cells from TILs was plotted (Fig. 3B) , patients with early disease showed higher levels of Th17 cells and lower levels of T reg cells compared with patients with advanced disease (P < 0.05). Thus, the balance of Th17/T reg in tumour microenvironments shifted from Th17dominant to T reg -dominant with disease progression.
CYTOKINE PRODUCTION BY T CELLS
The level of IL-17 production significantly correlated with the prevalence of Th17 cells, confirming the presence of Th17 cells and the quantitative accuracy of the flow cytometry analysis (P < 0.01; Fig. 4 ). There was no significant correlation between the prevalence of Th17 cells and the production of IL-21 or IL-23.
Discussion
The present study provides a quantitative and comprehensive analysis regarding the Th17/T reg cell balance in relation to disease progression in breast cancer, using TILs and PBMCs from patients with early and advanced breast cancer. Importantly, the accumulation of both Th17 cells and T reg cells in the tumour microenvironment was shown to occur at an early stage of the disease, with Th17 cell infiltration gradually decreasing and T reg cell infiltration increasing with disease progression. This finding is consistent with a report on prostate cancer in which an inverse correlation was noted between Th17 levels and tumour grade. 27 Several previous reports have described Th17 cells in human cancer. The accumulation of Th17 cells has been observed in TILs in prostate, 27, 29 myeloma, 30 -32 renal 33,34 and ovarian cancer. 15,35 -38 Thus, it is likely that Th17 cells accumulate in breast cancer tumours at an early disease stage and that Th17 levels in the tumour microenvironment decrease with tumour progression. 
Advanced stage T reg and Th17 cells in breast cancer
In contrast to the present study in humans, Th17 cells have been shown to increase in mouse models following tumour development, reaching maximum levels in advanced tumours. 39 This discrepancy may be explained by differences in murine and human tumour biology: transplantable tumours are implanted and grow rapidly in murine tumour models, whereas human tumours develop gradually and grow slowly. Thus, it is likely that the cytokine profile in the tumour microenvironment differs between murine and human cancer. It has, in fact, been shown that the biology of human cancer may reflect chronic or recurrent inflammation, which is different to murine models. 40 -42 Data on human Th17 cells indicate that IL-23 is an important inducer of human Th17 cell differentiation and that Th17 polarization is induced by IL-1β, possibly enhanced by IL-6, and may be suppressed by transforming growth factor-β (TGF-β). 43 -45 Thus, the fact that an increase in Th17 cells was observed in the present study in early breast cancer and a gradual decrease in Th17 cells occurred in advanced disease may reflect the local cytokine milieu including IL-21, IL-23, IL-1β, or TGF-β within the breast cancer tumour microenvironment. A direct correlation between the prevalence of Th17 cells and IL-21 production was not observed in the present study, nor was there any correlation between the prevalence of Th17 cells and IL-23 production. Furthermore, it has been shown that RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted) and monocyte chemotactic protein-1 secreted by tumour cells and tumour-derived fibroblasts within the microenvironment mediate Th17 cell recruitment. 46 Further studies to clarify the factors that regulate Th17 cells within the tumour microenvironment are needed.
The present study confirmed that the frequency of T reg cells in TILs was significantly higher than that in PBMCs from breast cancer patients and that T reg cells are already present in small localized tumours at the early stage of breast cancer. Taken together, the accumulation of both Th17 cells and T reg cells in the tumour microenvironment occurred at an early stage, with the infiltration of Th17 cells gradually decreasing in line with disease progression. This resulted in T reg cell dominance in the Th17/T reg balance in advanced stages of breast cancer. These observations in breast cancer are consistent with a report in ovarian cancer where the proportions of Th17 cells and T reg cells were inversely correlated. 37 Mechanisms behind the Th17/T reg balance in the tumour microenvironment are still under investigation, however the dynamic alterations seen may be caused by the variations in cytokine and chemokine profiles that occur with cancer progression. Although Th17 cells were reciprocally related to T reg cells in the present study, suggesting that Th17 has an important role in antitumour immunity, it remains controversial whether or not Th17 cells promote tumour growth or regulate an antitumour response. In one study, the frequency of IL-17 + CD4 + T-cell prevaccination was inversely correlated with the time to disease progression in 23 patients with prostate cancer. 27 In that study, Th17polarized cells were more effective than Th1 cells in eliminating large established tumours. These data imply an important role for Th17 cells in cancer immunology and highlight their potential use in pretreatment screening to ensure appropriate treatment and for antitumour immunotherapy. Alternatively, increased Th17 levels in early breast cancer may reflect the cytokine profile in acute inflammation, whereas decreased Th17 in advanced disease may reflect the cytokine profile in chronic and recurrent inflammation.
In conclusion, the accumulation of Th17 cells and T reg cells in the tumour microenvironment occurred at an early stage of breast cancer, with the infiltration of Th17 cells gradually decreasing and T reg cells increasing with disease progression. A better understanding of the underlying mechanisms that regulate the Th17/T reg cell balance may lead to novel therapeutic strategies for breast cancer.
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